Both are part of a new class of drugs known as GLP-1 receptor agonists, but they have some key differences in how they work and their overall efficacy
Staying informed and proactive about reporting contributes meaningfully to the safe development of new medicines for everyone
U40 Syringes: The Critical Difference A common misconception with Retatrutide administration is confusing U100 and U40 syringes
Opens in a new tab Does Medicare Part D cover GLP-1 Medications
has been on the advisory panel of, a consultant for, in the speaker's bureau of, owns shares in, and/or has received research support from 89bio, AstraZeneca, Boehringer Ingelheim, Cytoki Pharma, Eli Lilly, Gubra, Novo Nordisk, Merck Sharp & Dohme, Sanofi, Structure Therapeutics, Zealand Pharma, and Zucara
If additional glycemic control is needed, the dose may be increased to 1 mg weekly after at least four weeks, and potentially to a maximum of 2 mg weekly